Compare JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Nasdaq Equity Premium Income ETF vs Recursion Pharmaceuticals Inc — how do they compare? JPMorgan Nasdaq Equity Premium Income ETF trades at $61.1 (market cap $44.49B), while Recursion Pharmaceuticals Inc trades at $4.33 (market cap $2.14B). The key difference: JPMorgan Nasdaq Equity Premium Income ETF is far larger — about 20.8× Recursion Pharmaceuticals Inc's market cap, and JPMorgan Nasdaq Equity Premium Income ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Nasdaq Equity Premium Income ETF for 66 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| JEPQ | RXRX | |
|---|---|---|
Market Cap | $44.49B | $2.14B |
Volume | 5,681,789 | 30,789,535 |
Sector | Income / Options Overlay | Health |
52-Week High | $61.46 | $6.79 |
52-Week Low | $53.77 | $2.84 |
Typical Hold Time | 66 Days | 23 Days |
Enterprise Value | — | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPQ trades at $61.07, down 0.33% on the day, with technical indicators showing a bullish moving average signal but neutral oscillators. The ETF's covered-call strategy generates substantial monthly income, with recent dividends ranging from $0.57 to $0.70 per share. Financial media highlights JEPQ's 11% estimated yield and focus on Nasdaq technology exposure, though the strategy limits upside potential during strong bull markets.
JEPQ offers high monthly income through its covered-call approach on Nasdaq-100 stocks, making it attractive for income-focused investors. However, the strategy caps upside growth potential and distributions vary with market volatility. Key risks include concentrated tech exposure and dependence on options market conditions for income generation.
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
